Green Jeremy — SEC Form 4 filings
SEC reporting owner CIK 1650527. 38 Form 4 filings on record with FilingPulse; latest filed 2026-08-07.
Transaction summary — filings shown
Covers all 38 filings on record, filed 2024-02-09 to 2026-08-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 11 legs across 6 filings — 2,353,557 shares, $14,892,292 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 4 filings — 6,380,771 shares, $20,429,476 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 96.
- Largest priced transaction: sale of 2,634,506 shares @ $3.28 ($8,638,545) in ADC Therapeutics SA, filed 2026-04-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ADC Therapeutics SA (ADCT) | 10% owner | 8 | 6 legs · 1,000,000 sh · $2,857,000 | 7 legs · 5,905,767 sh · $19,688,819 | 34 |
| Attovia Therapeutics, Inc. (ATTO) | 10% owner | 1 | 2 legs · 600,000 sh · $10,200,000 | — | 2 |
| FATE THERAPEUTICS INC (FATE) | Director, 10% owner | 8 | 1 leg · 397,964 sh · $668,580 | 1 leg · 341,633 sh · $573,943 | 21 |
| Absci Corp (ABSI) | Director | 2 | 1 leg · 222,222 sh · $999,999 | — | 2 |
| Shattuck Labs, Inc. (STTK) | Director, 10% owner | 5 | 1 leg · 133,371 sh · $166,714 | 1 leg · 133,371 sh · $166,714 | 7 |
| IGM Biosciences, Inc. (IGMS) | 10% owner | 9 | — | — | 13 |
| Augmedix, Inc. (AUGX) | Director, 10% owner | 3 | — | — | 9 |
| Atara Biotherapeutics, Inc. (ATRA) | Director | 1 | — | — | 5 |
| Science 37 Holdings, Inc. (SNCE) | — | 1 | — | — | 3 |
Form 4 filings — Green Jeremy
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Attovia Therapeutics, Inc. (ATTO) jointly with Redmile Group, LLC, Redmile Biopharma Investments III, L.P. | Conversion (C): 782,854 · Purchase (P): 200,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 782,854 (derivative) | EDGAR |
| 2026-07-24 | 4 | Atara Biotherapeutics, Inc. (ATRA) jointly with Redmile Group, LLC | Option exercise (M): 195,211 · Tax withholding (F): 60 · Option exercise (M): 101,089 (derivative) @ $0 · Option exercise (M): 38,735 (derivative) @ $0 · Option exercise (M): 55,387 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Grant/award (A): 87,900 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4/A | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Other (J): 266,280 (derivative) @ $0 · Other (J): 266,280 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Other (J): 8,977,624 @ $0 · Other (J): 8,977,624 @ $0 · Other (J): 3,691,324 (derivative) @ $0 · Other (J): 3,691,324 (derivative) @ $0 · Other (J): 266,280 (derivative) @ $0 · Other (J): 266,280 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-02 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Sale (S): 196,229 @ $3.75 · Sale (S): 188,407 @ $3.75 · Sale (S): 169,265 @ $3.80 · Sale (S): 162,517 @ $3.80 · Sale (S): 2,634,506 @ $3.28 · Sale (S): 2,529,491 @ $3.28 | EDGAR |
| 2025-10-28 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 3,846,153 (derivative) @ $3.90 · Purchase (P): 3,846,153 (derivative) @ $3.90 | EDGAR |
| 2025-08-26 | 4 | Shattuck Labs, Inc. (STTK) jointly with Redmile Group, LLC | Grant/award (A): 4,097,730 (derivative) · Grant/award (A): 4,097,730 (derivative) | EDGAR |
| 2025-08-15 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Disposition to issuer (D): 2,964,843 · Disposition to issuer (D): 7,199,325 (derivative) · Disposition to issuer (D): 667,666 (derivative) | EDGAR |
| 2025-07-16 | 4 | Shattuck Labs, Inc. (STTK) jointly with Redmile Group, LLC | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 828 @ $0 | EDGAR |
| 2025-06-13 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 15,734,267 (derivative) @ $3.43 · Purchase (P): 12,465,234 (derivative) @ $3.43 | EDGAR |
| 2025-05-30 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 828 @ $0 | EDGAR |
| 2025-01-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 1,734 @ $0 | EDGAR |
| 2024-12-26 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Other (J): 1,084,936 @ $1.68 · Other (J): 1,084,936 @ $1.68 · Sale (S): 341,633 @ $1.68 · Purchase (P): 397,964 @ $1.68 · Other (J): 116,261 (derivative) @ $8.40 · Other (J): 116,261 (derivative) @ $8.40 · +1 more | EDGAR |
| 2024-12-16 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Conversion (C): 30,110 · Conversion (C): 6,022 (derivative) | EDGAR |
| 2024-12-13 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 50,000 @ $2.28 · Purchase (P): 50,000 @ $3.81 · Purchase (P): 50,000 @ $2.28 · Purchase (P): 50,000 @ $3.81 | EDGAR |
| 2024-12-06 | 4 | Shattuck Labs, Inc. (STTK) jointly with Redmile Group, LLC | Sale (S): 133,371 @ $1.25 · Purchase (P): 133,371 @ $1.25 · Other (J): 1,026,888 @ $1.25 · Other (J): 1,026,888 @ $1.25 | EDGAR |
| 2024-12-06 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Sale (S): 25,352 @ $2.07 · Other (J): 50,672 @ $2.07 · Other (J): 50,672 @ $2.07 · Other (J): 50,672 @ $2.07 · Other (J): 26,656 (derivative) @ $2.07 · Other (J): 26,656 (derivative) @ $2.07 · +1 more | EDGAR |
| 2024-10-04 | 4 | Augmedix, Inc. (AUGX) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P., Redmile Private Investments II, L.P. | Disposition to issuer (D): 16,421,788 @ $2.35 · Disposition to issuer (D): 9,446,146 @ $2.35 · Disposition to issuer (D): 6,218,238 @ $2.35 · Disposition to issuer (D): 3,125,195 (derivative) · Disposition to issuer (D): 3,125,195 (derivative) · Disposition to issuer (D): 1,093,799 (derivative) · +1 more | EDGAR |
| 2024-10-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 1,734 @ $0 | EDGAR |
| 2024-07-03 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 400,000 @ $2.81 · Purchase (P): 400,000 @ $2.81 | EDGAR |
| 2024-07-02 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 1,734 @ $0 | EDGAR |
| 2024-06-21 | 4 | Shattuck Labs, Inc. (STTK) jointly with Redmile Group, LLC | Grant/award (A): 27,700 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Augmedix, Inc. (AUGX) jointly with Redmile Group, LLC | Grant/award (A): 12,879 @ $0 | EDGAR |
| 2024-06-14 | 4 | Absci Corp (ABSI) jointly with Redmile Group, LLC | Grant/award (A): 8,820 @ $0 · Grant/award (A): 36,274 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 6,107,181 (derivative) @ $4.81 · Purchase (P): 8,163,265 (derivative) @ $4.81 | EDGAR |
| 2024-04-01 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Other (J): 12,464 @ $0 · Grant/award (A): 1,734 @ $0 | EDGAR |
| 2024-04-01 | 4 | Shattuck Labs, Inc. (STTK) jointly with Redmile Group, LLC | Other (J): 4,425 @ $0 | EDGAR |
| 2024-03-25 | 4 | FATE THERAPEUTICS INC (FATE) jointly with Redmile Group, LLC | Grant/award (A): 3,636,364 (derivative) @ $5.50 | EDGAR |
| 2024-03-19 | 4 | Augmedix, Inc. (AUGX) jointly with Redmile Group, LLC | Grant/award (A): 3,125 @ $0 | EDGAR |
| 2024-03-14 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Grant/award (A): 29,400 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Science 37 Holdings, Inc. (SNCE) jointly with Redmile Group, LLC | Code (U): 1,017,203 @ $5.75 · Disposition to issuer (D): 2,068 (derivative) · Disposition to issuer (D): 95,765 (derivative) | EDGAR |
| 2024-03-05 | 4 | Absci Corp (ABSI) jointly with Redmile Group, LLC | Purchase (P): 222,222 @ $4.50 | EDGAR |
| 2024-03-01 | 4 | IGM Biosciences, Inc. (IGMS) jointly with Redmile Group, LLC | Conversion (C): 113,400 @ $0 · Conversion (C): 113,400 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | ADC Therapeutics SA (ADCT) jointly with Redmile Group, LLC, RedCo II Master Fund, L.P. | Purchase (P): 56,900 (derivative) · Other (J): 59,986 (derivative) @ $1.68 · Purchase (P): 28,652 (derivative) · Purchase (P): 50,000 (derivative) · Purchase (P): 100,000 (derivative) · Purchase (P): 100,000 (derivative) · +16 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1650527 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →